Amalgamated Bank Increases Holdings in Edwards Lifesciences Corporation (EW)
Amalgamated Bank raised its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 53.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 24,656 shares of the medical research company’s stock after buying an additional 8,630 shares during the period. Amalgamated Bank’s holdings in Edwards Lifesciences Corporation were worth $2,915,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently made changes to their positions in EW. NEXT Financial Group Inc increased its stake in shares of Edwards Lifesciences Corporation by 91.7% in the 1st quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock worth $115,000 after purchasing an additional 500 shares in the last quarter. Shine Investment Advisory Services Inc. purchased a new stake in Edwards Lifesciences Corporation in the 2nd quarter worth $126,000. Cornerstone Advisors Inc. increased its stake in Edwards Lifesciences Corporation by 25.1% in the 2nd quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock worth $129,000 after buying an additional 219 shares in the last quarter. Alexandria Capital LLC increased its stake in Edwards Lifesciences Corporation by 1.7% in the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock worth $136,000 after buying an additional 19 shares in the last quarter. Finally, Captrust Financial Advisors purchased a new stake in Edwards Lifesciences Corporation in the 2nd quarter worth $149,000. Institutional investors and hedge funds own 82.36% of the company’s stock.
In related news, CEO Michael A. Mussallem sold 32,900 shares of the stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $112.45, for a total value of $3,699,605.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,600 shares of the stock in a transaction on Thursday, June 29th. The shares were sold at an average price of $117.15, for a total transaction of $656,040.00. The disclosure for this sale can be found here. Insiders sold a total of 163,541 shares of company stock worth $18,712,719 over the last ninety days. Insiders own 2.13% of the company’s stock.
Shares of Edwards Lifesciences Corporation (NYSE:EW) opened at 113.50 on Friday. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.75. The firm has a market capitalization of $23.97 billion, a P/E ratio of 34.43 and a beta of 0.64. The firm has a 50-day moving average of $113.99 and a 200 day moving average of $108.88.
Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 EPS for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The company had revenue of $842.00 million for the quarter, compared to the consensus estimate of $839.16 million. During the same period in the prior year, the firm posted $0.76 EPS. The company’s quarterly revenue was up 10.9% compared to the same quarter last year. On average, equities research analysts expect that Edwards Lifesciences Corporation will post $3.78 EPS for the current fiscal year.
EW has been the subject of a number of analyst reports. Zacks Investment Research upgraded Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $125.00 price target for the company in a research note on Monday, May 22nd. Jefferies Group LLC set a $115.00 price target on Edwards Lifesciences Corporation and gave the stock a “buy” rating in a research note on Saturday, May 27th. Bank of America Corporation increased their price target on Edwards Lifesciences Corporation from $120.00 to $140.00 and gave the stock a “buy” rating in a research note on Tuesday, May 30th. Royal Bank Of Canada reiterated a “buy” rating on shares of Edwards Lifesciences Corporation in a research note on Tuesday, May 30th. Finally, BidaskClub lowered Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Six analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. Edwards Lifesciences Corporation currently has a consensus rating of “Buy” and an average target price of $120.75.
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.